Sign up to save your podcasts
Or
Share ACCEL Lite: Omecamtiv Mecarbil and EF in the GALACTIC-HF Trial
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ACCEL Lite: Omecamtiv Mecarbil and EF in the GALACTIC-HF Trial
In this interview, Michelle O’Donoghue, MD, FACC; John Teerlink, MD, FACC; and Jeffrey Hsu, MD, PhD, discuss the effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in the GALACTIC-HF trial. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.
View all episodes
By American College of Cardiology
3.8
5454 ratings
In this interview, Michelle O’Donoghue, MD, FACC; John Teerlink, MD, FACC; and Jeffrey Hsu, MD, PhD, discuss the effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in the GALACTIC-HF trial. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.
More shows like ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
View all
JAMA Editors' Summary
137 Listeners
NEJM This Week
320 Listeners
JAMA Clinical Reviews
498 Listeners
JACC This Week
169 Listeners
This Week in Cardiology
885 Listeners
Mayo Clinic Talks
289 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
140 Listeners
Core IM | Internal Medicine Podcast
1,156 Listeners
ACC CardiaCast
41 Listeners
Annals On Call Podcast
195 Listeners
JAMA Medical News
90 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
364 Listeners
Cardionerds: A Cardiology Podcast
431 Listeners
The Curious Clinicians
371 Listeners
Mayo Clinic Cardiovascular CME
32 Listeners